Literature DB >> 9116473

Anxiety and Parkinson's disease.

I H Richard1, R B Schiffer, R Kurlan.   

Abstract

Anxiety disorders, particularly generalized anxiety, panic, and social phobia, occur in up to 40% of patients with Parkinson's disease (PD). This rate is higher than in normal or other disease comparison populations. Current evidence suggests that anxiety may not be a psychological reaction to the illness but rather may be linked to specific neurobiologic processes accompanying PD. Anxiety in PD often coexists with depression. The optimal pharmacologic treatment for anxiety in patients with PD has not been established, but available information about the use of anxiolytics in PD is reviewed. Further study of the relationship between anxiety and PD may provide an excellent opportunity to clarify the neurobiologic substrate of anxiety itself.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9116473     DOI: 10.1176/jnp.8.4.383

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  48 in total

1.  Nonrecognition of depression in Parkinson's disease.

Authors:  Karen E Anderson
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

Review 2.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

Review 3.  Recognition and management of neuropsychiatric complications in Parkinson's disease.

Authors:  Florian Ferreri; Catherine Agbokou; Serge Gauthier
Journal:  CMAJ       Date:  2006-12-05       Impact factor: 8.262

Review 4.  Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease.

Authors:  Yukihiro Ohno
Journal:  CNS Neurosci Ther       Date:  2010-11-21       Impact factor: 5.243

5.  Exercise effects on motor and affective behavior and catecholamine neurochemistry in the MPTP-lesioned mouse.

Authors:  Lori M Gorton; Marta G Vuckovic; Nina Vertelkina; Giselle M Petzinger; Michael W Jakowec; Ruth I Wood
Journal:  Behav Brain Res       Date:  2010-05-21       Impact factor: 3.332

6.  Attitudes regarding the etiology and treatment of depression in Parkinson's disease: a qualitative study.

Authors:  Katherine Oehlberg; Frances K Barg; Gregory K Brown; Donna Taraborelli; Matthew B Stern; Daniel Weintraub
Journal:  J Geriatr Psychiatry Neurol       Date:  2008-06       Impact factor: 2.680

7.  Panic disorder is associated with the serotonin transporter gene (SLC6A4) but not the promoter region (5-HTTLPR).

Authors:  L J Strug; R Suresh; A J Fyer; A Talati; P B Adams; W Li; S E Hodge; T C Gilliam; M M Weissman
Journal:  Mol Psychiatry       Date:  2008-07-29       Impact factor: 15.992

8.  Improving the Treatment of Parkinson's Disease: A Novel Approach by Modulating 5-HT(1A) Receptors.

Authors:  Saki Shimizu; Yukihiro Ohno
Journal:  Aging Dis       Date:  2012-11-29       Impact factor: 6.745

Review 9.  Parkinson disease: an update.

Authors:  Steven J Frucht
Journal:  Neurologist       Date:  2004-07       Impact factor: 1.398

Review 10.  Behavioral changes associated with deep brain stimulation surgery for Parkinson's disease.

Authors:  Karen E Anderson; Jake Mullins
Journal:  Curr Neurol Neurosci Rep       Date:  2003-07       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.